Among these studies, the use of the second-generation CAR T cells redirected to CD19 has manifested impressive therapeutic benefits in patients with B-cell malignancies [20], which led to FDA approval of CD19-CAR T-cell therapy for the treatment of B-cell acute lymphoblastic leukemia. The gene discussed is CD19; the disease is B-cell acute lymphoblastic leukemia.